We are live on
!
Find out more
PBPIA
Pivotal bioVenture Partners Investment Advisor Portfolio holdings
AUM
$308M
1-Year Est. Return
120.89%
This Fund
S&P 500
This Quarter
Est. Return
+12.17%
1 Year Est. Return
+120.89%
3 Year Est. Return
+667.1%
5 Year Est. Return
+1,484.61%
10 Year Est. Return
–
AUM
$308M
AUM Growth
+$28M
(+10%)
Cap. Flow
+$27.5M
Cap. Flow
% of AUM
8.92%
Top 10 Holdings %
Top 10 Hldgs %
95.12%
Holding
14
New
1
Increased
3
Reduced
4
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AVLN
Avalyn Pharma
AVLN
|
+$27.9M |
| 2 |
Vaxcyte
PCVX
|
+$2.88M |
| 3 |
Trevi Therapeutics
TRVI
|
+$2.75M |
| 4 |
Avalo Therapeutics
AVTX
|
+$2.18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oculis Holding
OCS
|
+$3.95M |
| 2 |
Arcutis Biotherapeutics
ARQT
|
+$2.11M |
| 3 |
ZBIO
Zenas BioPharma
ZBIO
|
+$2.01M |
| 4 |
Bolt Biotherapeutics
BOLT
|
+$172K |
| 5 |
MPLT
MapLight Therapeutics
MPLT
|
+$29 |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Vaxcyte
PCVX
$9.1B
| $82.9M | 26.92% |
1,425,470
+53,045
| +4% | +$2.88M |
|
|
2
Arcutis Biotherapeutics
ARQT
$3B
| $33.2M | 10.78% |
1,265,283
-90,609
| -7% | -$2.11M |
|
|
3
Trevi Therapeutics
TRVI
$2.46B
| $32.5M | 10.56% |
1,742,672
+188,946
| +12% | +$2.75M |
|
|
AVLN
4
Avalyn Pharma
AVLN
$1.66B
| $31.8M | 10.34% |
+966,792
| New | +$27.9M |
|
|
EVMN
5
Evommune Inc
EVMN
$445M
| $25.6M | 8.32% |
1,926,943
| – | – |
|
|
MPLT
6
MapLight Therapeutics
MPLT
$639M
| $21.9M | 7.12% |
611,446
-1
| -0% | -$29 |
|
|
7
Oculis Holding
OCS
$676M
| $20.9M | 6.79% |
1,506,250
-174,033
| -10% | -$3.95M |
|
|
BIOA
8
BioAge Labs
BIOA
$440M
| $16M | 5.2% |
653,374
| – | – |
|
9
Immunome
IMNM
$3.04B
| $15.5M | 5.04% |
732,512
| – | – |
|
|
ZBIO
10
Zenas BioPharma
ZBIO
$2.14B
| $12.5M | 4.05% |
490,766
-101,225
| -17% | -$2.01M |
|
|
11
Avalo Therapeutics
AVTX
$1.03B
| $8.02M | 2.61% |
434,033
+138,100
| +47% | +$2.18M |
|
12
Rallybio
RLYB
$89.9M
| $4.81M | 1.56% |
300,579
| – | – |
|
13
Recursion Pharmaceuticals
RXRX
$1.95B
| $2.19M | 0.71% |
595,518
| – | – |
|
|
14
Bolt Biotherapeutics
BOLT
$7.51M
| – | – |
-42,581
| Closed | -$172K |
|
Similar funds
LCC
AWAP
KFS
FIG
DC
ECH
GL
FCT
Pivotal bioVenture Partners Investment Advisor's Q2 2026 Portfolio in Review
As of Q2 2026, Pivotal bioVenture Partners Investment Advisor held 14 positions worth $308M, up 10% from $280M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
Pivotal bioVenture Partners Investment Advisor deployed $27.5M of net new capital in Q2 2026, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Avalyn Pharma: 966,792 shares worth $31.8M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Oculis Holding, an estimated $3.95M trimmed.
- Pivotal bioVenture Partners Investment Advisor's largest Q2 2026 buy was Avalyn Pharma: 966,792 shares worth $31.8M.
- Pivotal bioVenture Partners Investment Advisor added most to Vaxcyte in Q2 2026, an estimated $2.88M increase.
- Pivotal bioVenture Partners Investment Advisor's biggest Q2 2026 reduction was Oculis Holding, cutting an estimated $3.95M.
- Pivotal bioVenture Partners Investment Advisor fully exited Bolt Biotherapeutics in Q2 2026, selling an estimated $172K.
- Pivotal bioVenture Partners Investment Advisor's ten largest holdings make up 95% of its $308M portfolio in Q2 2026.
- Pivotal bioVenture Partners Investment Advisor opened 1 new position and closed 1 in Q2 2026.
- Pivotal bioVenture Partners Investment Advisor's portfolio value rose 10% quarter-over-quarter to $308M.
Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q2 2026, filed 13 Aug 2026.